Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Angela Duffy
  • March 18, 2020
  • Articles

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Mapping the patient journey and minding the gap: Seven steps to closing the gap between rhetoric and reality in patient-centricity

Senior Director Angela Duffy was recently interviewed by PME Magazine about the steps needed to close the gap between rhetoric and reality in patient-centricity, and why it’s vital to include patients in every step.

“When I grew up in the industry, things were pretty well set in terms of how pharmaceutical companies engaged with patients - which is to say that you didn’t engage all that much.” Ron Cohen’s reflection on ‘Pharma Past’ will be familiar to many who worked in the industry in the era before patient-centricity became the biggest of buzzwords. Speaking to McKinsey in 2016, the biotech CEO argued that a new generation of engagement was dawning. 

read more »

  • Posted by Ellie Forde
  • February 18, 2020
  • Articles

3 trends the healthcare market research industry should watch out for over the next decade

3 trends the healthcare market research industry should watch out for over the next decade

As we head into the 2020s, Associate Director Ellie Forde considers the key trends that might impact healthcare over the next 10 years and the possible impacts on market research.

My colleague Rachel Howard wrote a blog at the end of last year reviewing her predictions in 2010 for the coming decade. As we head into the 2020s, I thought it might be timely to consider the key trends that might impact healthcare over the next 10 years. With technology advancing at an ever-increasing pace, these may be many, but I want to focus on what I believe are three of the big ‘watch outs’, and those I am personally excited about. 

read more »

  • Posted by Paul Reed
  • February 14, 2020
  • Articles

Exploring Saudi Arabia

Exploring Saudi Arabia

Is it the right climate for nutritional health products?

As a country with a ferociously hot climate, Saudi Arabia relies heavily on imports to maintain its food supplies. The country also faces a looming demographic imbalance, in which a top-heavy population can rely less and less on the resources and tax revenues of the young. Saudi now has to cope with a rapidly accumulating burden of disease related to population aging, westernised diets and more sedentary lifestyles. Sharp increases in cardiovascular disease, cancer, arthritis and other age-associated conditions, as well as surging levels of obesity and diabetes all give cause for alarm. Around 57% of men and 61% of women in Saudi are considered overweight or obese and around 3.8 million adults in the region are living with diabetes.

read more »

  • Posted by Rachel Howard
  • February 12, 2020
  • Articles

Beyond BRIC, Into MIST: Setting sights on pharma’s next-tier terrain

Beyond BRIC, Into MIST: Setting sights on pharma’s next-tier terrain

Emerging markets Director Rachel Howard was recently interviewed by Julian Upton from Pharmaceutical Executive about the BRIC and MIST pharma markets, and what to look out for over the next few years.

Although the BRIC countries (Brazil, Russia, India, China) or BRICS (if we add South Africa) tend to dominate discussions of “emerging” pharma markets, it is useful to cast an eye over “MIST,” another catchy acronym coined by economist Jim O’Neill that comprises Mexico, Indonesia, South Korea, and Turkey. In terms of their pharma markets, Attieh and Tannoury noted in 2017 that sales in both BRICS and MIST countries had doubled in five years, reaching a market share of approximately 20%, while McKinsey & Company, choosing to group Mexico and Turkey with BRIC, observed that these “BRICMT countries” would be instrumental in driving an expected USD$190 billion of pharma sales growth between 2015 and 2020. Given the volatile political and economic factors affecting some emerging market countries, however, the question of whether BRIC or MIST remain useful as pharma-market groupings is worth considering as we move into 2020 and beyond.

read more »

Catching up with Coronavirus: The race to contain the outbreak is on

Catching up with Coronavirus: The race to contain the outbreak is on

As Coronavirus continues to spread across the globe, Rachel Howard explores what pharma is doing to advance research into the virus, considering lessons learned from previous public health emergencies of international concern.

Over the last month, our newsfeeds have increasingly been dominated by updates on the novel coronavirus (COVID-19) outbreak. Believed to have originated in a live animal market in the Chinese city of Wuhan, at the time of publishing COVID-19 has registered over 75,000 confirmed cases and 2000 deaths, with 29 countries and territories affected. nCoV is in the same family as SARS (Severe Acute Respiratory Syndrome), another strain of coronavirus identified in 2003. While nCoV looks likely to have a lower fatality rate, it has spread much more quickly, with the number of reported cases already having rapidly overtaken SARS and continuing to grow by the day. All indications suggest the virus is highly contagious – including, critically, at the stage before an individual displays any symptoms of infection. This outbreak was declared as a public health emergency of international concern (PHEIC) by the World Health Organization (WHO) on 30th January 2020, making it the sixth such emergency since the International Health Regulations came into force in 2005: H1N1 influenza virus (swine flu) in 2009 Wild poliovirus resurgence in 2014 West Africa Ebola virus 2014 Zika virus in 2016 Kivu Ebola virus in 2019 Declaring an outbreak as a PHEIC, in…

read more »